Management of patients with myoclonus: Available therapies and the need for an evidence-based approach

The Lancet Neurology

Volumn 9, Issue 10, 2010, Pages 1028-1036

  Dijk, Joke M ^a   Tijssen, Marina A J ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYTRYPTOPHAN; BACLOFEN; BARBITURIC ACID DERIVATIVE; BOTULINUM TOXIN; CARBAMAZEPINE; CARBIDOPA; CARBIDOPA PLUS LEVODOPA; CHOLINERGIC RECEPTOR BLOCKING AGENT; CLONAZEPAM; CORTICOTROPIN; ETIRACETAM; HYDANTOIN; IMMUNOGLOBULIN; LAMOTRIGINE; LEVODOPA; LISURIDE; MILACEMIDE; OXYBATE SODIUM; PHENOBARBITAL; PHENYTOIN; PIRACETAM; PRIMIDONE; RITUXIMAB; SUMATRIPTAN; TETRABENAZINE; TRIHEXYPHENIDYL; UNINDEXED DRUG; VALPROIC ACID; VIGABATRIN; ZOLPIDEM;

ABDOMINAL PAIN; AGGRESSION; ANOREXIA; ANXIETY; ATAXIA; BEHAVIOR DISORDER; BRANCHIAL MYOCLONUS; CLINICAL FEATURE; CLINICAL TRIAL; CORTICAL MYOCLONUS; DIARRHEA; DISEASE CLASSIFICATION; DIZZINESS; DROWSINESS; DRUG ERUPTION; DYSPHAGIA; DYSPNEA; EVIDENCE BASED PRACTICE; FLATULENCE; HUMAN; HYPEREKPLEXIA; LOW DRUG DOSE; MENTAL DISEASE; MYDRIASIS; MYOCLONUS; MYOCLONUS DYSTONIA; MYOCLONUS EPILEPSY; NAUSEA; OPSOCLONUS MYOCLONUS SYNDROME; ORTHOSTATIC MYOCLONUS; PALATE MYOCLONUS; PALATOPHARYNGEAL INCOMPETENCE; PERIPHERAL MYOCLONUS; PRIORITY JOURNAL; PSYCHOGENIC MYOCLONUS; RETICULAR REFLEX MYOCLONUS; REVIEW; SEDATION; SIDE EFFECT; SLEEP DISORDER; SPINAL MYOCLONUS; STOMACH DISCOMFORT; SUBCORTICAL MYOCLONUS; UNSPECIFIED SIDE EFFECT; URTICARIA; VOICE CHANGE; VOMITING; ANIMAL; CLASSIFICATION; DISEASE MANAGEMENT; EVIDENCE BASED MEDICINE; PROCEDURES; TRENDS;

ANIMALS; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; HUMANS; MYOCLONUS;

EID: 77956862226     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(10)70193-9     Document Type: Review

References (103)

1. Fahn S, Marsden CD, Van Woert MH Definition and classification of myoclonus. Adv Neurol 1986, 43:1-5.
2. Rubboli G, Tassinari CA Negative myoclonus. An overview of its clinical features, pathophysiological mechanisms, and management. Neurophysiol Clin 2006, 36:337-343.
3. Caviness JN, Alving LI, Maraganore DM, Black RA, McDonnell SK, Rocca WA The incidence and prevalence of myoclonus in Olmsted County, Minnesota. Mayo Clin Proc 1999, 74:565-569.
4. Tse W, Libow LS, Neufeld R, et al. Prevalence of movement disorders in an elderly nursing home population. Arch Gerontol Geriatr 2008, 46:359-366.
5. Yoon JH, Lee PH, Yong SW, Park HY, Lim TS, Choi JY Movement disorders at a university hospital emergency room. An analysis of clinical pattern and etiology. J Neurol 2008, 255:745-749.
6. Marsden CD, Hallet M, Fahn S The nosology and pathophysiology of myoclonus. Movement disorders 1982, 196-248. Butterworths, London. C.D. Marsden, S. Fahn (Eds.).
7. Faught E Clinical presentations and phenomenology of myoclonus. Epilepsia 2003, 44(suppl 11):7-12.
8. Jankovic J Treatment of hyperkinetic movement disorders. Lancet Neurol 2009, 8:844-856.
9. Agarwal P, Frucht SJ Myoclonus. Curr Opin Neurol 2003, 16:515-521.
10. Hinson VK, Haren WB Psychogenic movement disorders. Lancet Neurol 2006, 5:695-700.
11. Shibasaki H, Hallett M Electrophysiological studies of myoclonus. Muscle Nerve 2005, 31:157-174.
12. Caviness JN Pathophysiology and treatment of myoclonus. Neurol Clin 2009, 27:757-777.
13. Jimenez-Jimenez FJ, Puertas I, de Toledo-Heras M Drug-induced myoclonus: frequency, mechanisms and management. CNS Drugs 2004, 18:93-104.
14. Andrade DM, Hamani C, Minassian BA Treatment options for epileptic myoclonus and epilepsy syndromes associated with myoclonus. Expert Opin Pharmacother 2009, 10:1549-1560.
15. Wheless JW, Sankar R Treatment strategies for myoclonic seizures and epilepsy syndromes with myoclonic seizures. Epilepsia 2003, 44(suppl 11):27-37.
16. Wallace SJ Myoclonus and epilepsy in childhood: a review of treatment with valproate, ethosuximide, lamotrigine and zonisamide. Epilepsy Res 1998, 29:147-154.
17. Fahn S Overview, history and classification of myoclonus. Myoclonus and paroxysmal dyskinesias 2002, 13-17. Lippincot Williams & Wilkins, Philadelphia. S. Fahn, S.J. Frucht, M. Hallet, D.D. Truong (Eds.).
18. Caviness JN, Brown P Myoclonus: current concepts and recent advances. Lancet Neurol 2004, 3:598-607.
19. Obeso JA Therapy of myoclonus. Clin Neurosci 1995, 3:253-257.
20. Frucht S, Fahn S The clinical spectrum of posthypoxic myoclonus. Mov Disord 2000, 15(suppl 1):2-7.
21. Lang AE Essential myoclonus and myoclonic dystonia. Mov Disord 1997, 12:127.
22. Quinn NP Essential myoclonus and myoclonic dystonia. Mov Disord 1996, 11:119-124.
23. Monday K, Jankovic J Psychogenic myoclonus. Neurology 1993, 43:349-352.
24. Thomas M, Jankovic J Psychogenic movement disorders: diagnosis and management. CNS Drugs 2004, 18:437-452.
25. Terada K, Ikeda A, Van Ness PC, et al. Presence of Bereitschaftspotential preceding psychogenic myoclonus: clinical application of jerk-locked back averaging. J Neurol Neurosurg Psychiatry 1995, 58:745-747.
26. Shibasaki H, Hallett M What is the Bereitschaftspotential?. Clin Neurophysiol 2006, 117:2341-2356.
27. Tijssen MAJ, Tijssen CC Myoclonus. Parkinsonism and related disorders 2007, VU University Press, Amsterdam. E.C. Wolters, T. van Laar, H.W. Berendse (Eds.).
28. Shibasaki H, Yamashita Y, Kuroiwa Y Electroencephalographic studies myoclonus. Brain 1978, 101:447-460.
29. Brown P, Farmer SF, Halliday DM, Marsden J, Rosenberg JR Coherent cortical and muscle discharge in cortical myoclonus. Brain 1999, 122:461-472.
30. Grosse P, Cassidy MJ, Brown P EEG-EMG, MEG-EMG and EMG-EMG frequency analysis: physiological principles and clinical applications. Clin Neurophysiol 2002, 113:1523-1531.
31. Shibasaki H, Yamashita Y, Neshige R, Tobimatsu S, Fukui R Pathogenesis of giant somatosensory evoked potentials in progressive myoclonic epilepsy. Brain 1985, 108:225-240.
32. Hallett M Physiology of human posthypoxic myoclonus. Mov Disord 2000, 15(suppl 1):8-13.
33. Chadwick D, Hallett M, Harris R, Jenner P, Reynolds EH, Marsden CD Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain 1977, 100:455-487.
34. Gerschlager W, Brown P Myoclonus. Curr Opin Neurol 2009, 22:414-418.
35. Alvarez M, Caviness JN Primary progressive myoclonus of aging. Mov Disord 2008, 23:1658-1664.
36. Roze E, Apartis E, Clot F, et al. Myoclonus-dystonia: clinical and electrophysiologic pattern related to SGCE mutations. Neurology 2008, 70:1010-1016.
37. Kinugawa K, Vidailhet M, Clot F, Apartis E, Grabli D, Roze E Myoclonus-dystonia: an update. Mov Disord 2009, 24:479-489.
38. Foncke EM, Cath D, Zwinderman K, Smit J, Schmand B, Tijssen M Is psychopathology part of the phenotypic spectrum of myoclonus-dystonia?: a study of a large Dutch M-D family. Cogn Behav Neurol 2009, 22:127-133.
39. Bakker MJ, van Dijk JG, van den Maagdenberg AM, Tijssen MA Startle syndromes. Lancet Neurol 2006, 5:513-524.
40. Brown P, Rothwell JC, Thompson PD, Britton TC, Day BL, Marsden CD The hyperekplexias and their relationship to the normal startle reflex. Brain 1991, 114:1903-1928.
41. Krug P, Schleiermacher G, Michon J, et al. Opsoclonus-myoclonus in children associated or not with neuroblastoma. Eur J Paediatr Neurol 2010, 14:400-409.
42. Tate ED, Allison TJ, Pranzatelli MR, Verhulst SJ Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome. J Pediatr Oncol Nurs 2005, 22:8-19.
43. Dalmau J, Rosenfeld MR Paraneoplastic syndromes of the CNS. Lancet Neurol 2008, 7:327-340.
44. Gwinn KA, Caviness JN Electrophysiological observations in idiopathic opsoclonus-myoclonus syndrome. Mov Disord 1997, 12:438-442.
45. Zadikoff C, Lang AE, Klein C The 'essentials' of essential palatal tremor: a reappraisal of the nosology. Brain 2006, 129:832-840.
46. Deuschl G, Toro C, Valls-Sole J, Zeffiro T, Zee DS, Hallett M Symptomatic and essential palatal tremor. Clinical, physiological and MRI analysis. Brain 1994, 117:775-788.
47. Zadikoff C, Lang AE, Klein C The 'essentials' of essential palatal tremor: a reappraisal of the nosology. Brain 2006, 129:832-840.
48. Deuschl G, Mischke G, Schenck E, Schulte-Monting J, Lucking CH Symptomatic and essential rhythmic palatal myoclonus. Brain 1990, 113:1645-1672.
49. Glass GA, Ahlskog JE, Matsumoto JY Orthostatic myoclonus: a contributor to gait decline in selected elderly. Neurology 2007, 68:1826-1830.
50. Leu-Semenescu S, Roze E, Vidailhet M, et al. Myoclonus or tremor in orthostatism: an under-recognized cause of unsteadiness in Parkinson's disease. Mov Disord 2007, 22:2063-2069.
51. Esposito M, Edwards MJ, Bhatia KP, Brown P, Cordivari C Idiopathic spinal myoclonus: a clinical and neurophysiological assessment of a movement disorder of uncertain origin. Mov Disord 2009, 24:2344-2349.
52. Roze E, Bounolleau P, Ducreux D, et al. Propriospinal myoclonus revisited: clinical, neurophysiologic, and neuroradiologic findings. Neurology 2009, 72:1301-1309.
53. van der Salm SM, Koelman JH, Henneke S, van Rootselaar AF, Tijssen MA Axial jerks: a clinical spectrum ranging from propriospinal to psychogenic myoclonus. J Neurol 2010, 257:1349-1355.
54. Jankovic J Peripherally induced movement disorders. Neurol Clin 2009, 27:821-832.
55. Nilsen B, Le KD, Dietrichs E Prevalence of hemifacial spasm in Oslo, Norway. Neurology 2004, 63:1532-1533.
56. Wang A, Jankovic J Hemifacial spasm: clinical findings and treatment. Muscle Nerve 1998, 21:1740-1747.
57. Banks G, Nielsen VK, Short MP, Kowal CD Brachial plexus myoclonus. J Neurol Neurosurg Psychiatry 1985, 48:582-584.
58. Seidel G, Vieregge P, Wessel K, Kompf D Peripheral myoclonus due to spinal root lesion. Muscle Nerve 1997, 20:1602-1603.
59. Camerota F, Celletti C, Paoloni M, et al. Myoclonus of the scapula after acute long thoracic nerve lesion: a case report. Mov Disord 2006, 21:71-73.
60. Tyvaert L, Krystkowiak P, Cassim F, et al. Myoclonus of peripheral origin: two case reports. Mov Disord 2009, 24:274-277.
61. Nirenberg MJ, Frucht SJ Myoclonus. Curr Treat Options Neurol 2005, 7:221-230.
62. Obeso JA, Artieda J, Rothwell JC, Day B, Thompson P, Marsden CD The treatment of severe action myoclonus. Brain 1989, 112:765-777.
63. French J, Gronseth G Lost in a jungle of evidence: we need a compass. Neurology 2008, 71:1634-1638.
64. Gronseth G, French J Practice parameters and technology assessments: what they are, what they are not, and why you should care. Neurology 2008, 71:1639-1643.
65. Goldberg MA, Dorman JD Intention myoclonus: successful treatment with clonazepam. Neurology 1976, 26:24-26.
66. Obeso JA, Rothwell JC, Quinn NP Cortical reflex myoclonus responds to intravenous lisuride. Clin Neuropharmacol 1983, 6:231-240.
67. Van Woert MH, Rosenbaum D L-5-hydroxytryptophan therapy in myoclonus. Adv Neurol 1979, 26:107-115.
68. Klawans HL, Goetz C, Bergen D Levodopa-Induced Myoclonus. Arch Neurol 1975, 32:331-334.
69. Gordon MF, az-Olivo R, Hunt AL, Fahn S Therapeutic trial of milacemide in patients with myoclonus and other intractable movement disorders. Mov Disord 1993, 8:484-488.
70. Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993, 8:63-68.
71. Obeso JA, Artieda J, Quinn N, et al. Piracetam in the treatment of different types of myoclonus. Clin Neuropharmacol 1988, 11:529-536.
72. Saft C, Lauter T, Kraus PH, Przuntek H, Andrich JE Dose-dependent improvement of myoclonic hyperkinesia due to Valproic acid in eight Huntington's Disease patients: a case series. BMC Neurol 2006, 6:11.
73. Koskiniemi M, Van VB, Hakamies L, Lamusuo S, Taalas J Piracetam relieves symptoms in progressive myoclonus epilepsy: a multicentre, randomised, double blind, crossover study comparing the efficacy and safety of three dosages of oral piracetam with placebo. J Neurol Neurosurg Psychiatry 1998, 64:344-348.
74. Chang VC, Frucht SJ Myoclonus. Curr Treat Options Neurol 2008, 10:222-229.
75. Noachtar S, Andermann E, Meyvisch P, Andermann F, Gough WB, Schiemann-Delgado J Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008, 70:607-616.
76. Frucht SJ, Louis ED, Chuang C, Fahn S A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001, 57:1112-1114.
77. Muslu B, Kilci O, Horasanli E, Dikmen B Dramatic effect of levetiracetam on posthypoxic myoclonus: difficult weaning from mechanical ventilation. Clin Neuropharmacol 2009, 32:236.
78. Fahn S Posthypoxic action myoclonus: review of the literature and report of two new cases with response to valproate and estrogen. Adv Neurol 1979, 26:49-84.
79. Pranzatelli MR, Huang Y-Y, Tate E, et al. Monoaminergic effects of high-dose corticotropin in corticotropin-responsive pediatric opsoclonus-myoclonus. Mov Disord 1998, 13:522-528.
80. Przuntek H, Muhr H Essential familial myoclonus. J Neurol 1983, 230:153-162.
81. Penney SE, Bruce IA, Saeed SR Botulinum toxin is effective and safe for palatal tremor: a report of five cases and a review of the literature. J Neurol 2006, 253:857-860.
82. Jankovic J, Pardo R Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol 1986, 43:1025-1031.
83. Pranzatelli MR, Tate E, Huang Y, Baldwin M Clinical response to 5-hydroxy-L-tryptophan in chronic pediatric opsoclonus-myoclonus: a double-blind placebo crossover pilot study. Clin Neuropharmacol 1994, 17:103-116.
84. Pranzatelli MR, Tate ED, Galvan I, Wheeler A Controlled pilot study of piracetam for pediatric opsoclonus-myoclonus. Clin Neuropharmacol 2001, 24:352-357.
85. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006, 28:585-593.
86. Mundinger F, Kuhn I Postoperative and long-term results after stereotactic operations for action myoclonia in cases of encephalomyelitis disseminata. Appl Neurophysiol 1982, 45:299-305.
87. East CA, Hazell JWP The supression of palatal (or intra-tympanic) myclonus by tinnitus masking devices. A preliminary report. J Laryngol Otol 1987, 101:1230-1234.
88. Frucht SJ, Houghton WC, Bordelon Y, Greene PE, Louis ED A single-blind, open-label trial of sodium oxybate for myoclonus and essential tremor. Neurology 2005, 65:1967-1969.
89. Luciano MS, Ozelius L, Sims K, Raymond D, Liu L, Saunders-Pullman R Responsiveness to levodopa in epsilon-sarcoglycan deletions. Mov Disord 2009, 24:425-428.
90. Park IS, Kim JS, An JY, Kim YI, Lee KS Excellent response to oral zolpidem in a sporadic case of the myoclonus dystonia syndrome. Mov Disord 2009, 24:2172-2173.
91. Tijssen MA, Schoemaker HC, Edelbroek PJ, Roos RA, Cohen AF, van Dijk JG The effects of clonazepam and vigabatrin in hyperekplexia. J Neurol Sci 1997, 149:63-67.
92. Bakker MJ, Peeters EA, Tijssen MA Clonazepam is an effective treatment for hyperekplexia due to a SLC6A5 (GlyT2) mutation. Mov Disord 2009, 24:1852-1854.
93. Pless M, Ronthal M Treatment of opsoclonus-myoclonus with high-dose intravenous immunoglobulin. Neurology 1996, 46:583-584.
94. Bartos A Effective high-dose clonazepam treatment in two patients with opsoclonus and myoclonus: GABAergic hypothesis. Eur Neurol 2006, 56:240-242.
95. Lagueny A, Tison F, Burbaud P, Le MG, Kien P Stimulus-sensitive spinal segmental myoclonus improved with injections of botulinum toxin type A. Mov Disord 1999, 14:182-185.
96. Yoshimura DM, Aminoff MJ, Tami TA, Scott AB Treatment of hemifacial spasm with botulinum toxin. Muscle Nerve 1992, 15:1045-1049.
97. Costa J, Espirito-Santo C, Borges A, et al. Botulinum toxin type A therapy for hemifacial spasm. Cochrane Database Syst Rev 2005, 1. CD004899.
98. Kenney C, Jankovic J Botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neural Transm 2008, 115:585-591.
99. Jost WH, Kohl A Botulinum toxin: evidence-based medicine criteria in blepharospasm and hemifacial spasm. J Neurol 2001, 248(suppl 1):21-24.
100. Stone J, Carson A, Sharpe M Functional symptoms in neurology: management. J Neurol Neurosurg Psychiatry 2005, 76(suppl 1):13-21.
101. Kroenke K, Swindle R Cognitive-behavioral therapy for somatization and symptom syndromes: a critical review of controlled clinical trials. Psychother Psychosom 2000, 69:205-215.
102. Thomas M, Vuong KD, Jankovic J Long-term prognosis of patients with psychogenic movement disorders. Parkinsonism Relat Disord 2006, 12:382-387.
103. Feinstein A, Stergiopoulos V, Fine J, Lang AE Psychiatric outcome in patients with a psychogenic movement disorder: a prospective study. Neuropsychiatry Neuropsychol Behav Neurol 2001, 14:169-176.